Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Apr 9, 2024
Discovery & Translation
AACR brings new modalities, new targets to glioblastoma
BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Oct 29, 2021
Emerging Company Profile
Walden: targeting podocytes as linchpin for kidney function
Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases
BioCentury | Jun 20, 2020
Translation in Brief
CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more
Items per page:
1 - 10 of 11